Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
TMO 
Thermo Fisher Scientific Inc (TMO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: TMO (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -27.71% | Avg. Invested days 36 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 182.21B USD | Price to earnings Ratio 29.24 | 1Y Target Price 659.08 |
Price to earnings Ratio 29.24 | 1Y Target Price 659.08 | ||
Volume (30-day avg) 1752752 | Beta 0.79 | 52 Weeks Range 481.21 - 626.49 | Updated Date 04/1/2025 |
52 Weeks Range 481.21 - 626.49 | Updated Date 04/1/2025 | ||
Dividends yield (FY) 0.35% | Basic EPS (TTM) 16.52 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 14.77% | Operating Margin (TTM) 19.43% |
Management Effectiveness
Return on Assets (TTM) 4.9% | Return on Equity (TTM) 13.13% |
Valuation
Trailing PE 29.24 | Forward PE 20.75 | Enterprise Value 207910833070 | Price to Sales(TTM) 4.25 |
Enterprise Value 207910833070 | Price to Sales(TTM) 4.25 | ||
Enterprise Value to Revenue 4.85 | Enterprise Value to EBITDA 18.02 | Shares Outstanding 377260992 | Shares Floating 376450070 |
Shares Outstanding 377260992 | Shares Floating 376450070 | ||
Percent Insiders 0.2 | Percent Institutions 92.53 |
Analyst Ratings
Rating 4.38 | Target Price 646.08 | Buy 8 | Strong Buy 18 |
Buy 8 | Strong Buy 18 | ||
Hold 6 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Thermo Fisher Scientific Inc
Company Overview
History and Background
Thermo Fisher Scientific Inc. was formed in 2006 through the merger of Thermo Electron and Fisher Scientific. Thermo Electron was founded in 1956, and Fisher Scientific in 1902. It has grown through numerous acquisitions to become a leading provider of scientific instruments, reagents and consumables, and software and services.
Core Business Areas
- Life Sciences Solutions: Provides a broad range of reagents, instruments, and consumables used in biological research, drug discovery, and bioproduction. Includes cell culture products, PCR technologies, and genetic analysis systems.
- Analytical Instruments: Offers instruments and solutions for chromatography, mass spectrometry, spectroscopy, and elemental analysis used in research, quality control, and environmental monitoring.
- Specialty Diagnostics: Develops and manufactures diagnostic test kits, reagents, instruments, and controls used in clinical laboratories and point-of-care settings.
- Laboratory Products and Biopharma Services: Provides a comprehensive range of laboratory equipment, chemicals, and consumables, as well as bioproduction services, including contract development and manufacturing of biologics.
Leadership and Structure
Marc N. Casper serves as the Chairman, President, and Chief Executive Officer. The company is organized into the four business segments mentioned above, with a corporate structure overseeing strategic direction and operational efficiency.
Top Products and Market Share
Key Offerings
- Mass Spectrometry: Mass spectrometry instruments are used for analyzing the chemical composition of substances. Thermo Fisher is a major player in this field. Competitors include Agilent and Waters Corporation. Revenue from this product line is significant, contributing to overall Analytical Instruments segment revenue. Data not published separately, estimated in Billions USD. Market share approximately 30-35% in the overall mass spec market.
- PCR Technologies: Polymerase chain reaction (PCR) technologies are essential for DNA amplification and analysis. Thermo Fisher offers a range of PCR instruments, reagents, and kits. Competitors include Roche and QIAGEN. Revenue in the billions, exact number not publised seprately. Market share approximately 20-25% in the PCR market during normal years.
- Cell Culture Products: Thermo Fisher provides cell culture media, sera, and supplements for growing cells in vitro. Competitors include Merck Millipore and Corning. Part of Life Sciences Solutions and contribute Billions to this segment.
Market Dynamics
Industry Overview
The life sciences and diagnostics industry is characterized by innovation, increasing regulatory scrutiny, and growing demand for personalized medicine. Increasing R&D spending and technological advancements are driving growth. The market is expanding due to the increased need for diagnostics and therapeutics.
Positioning
Thermo Fisher Scientific Inc. holds a leading position in the industry due to its broad product portfolio, global presence, and strong brand reputation. Its competitive advantages include its scale, innovation capabilities, and customer relationships.
Total Addressable Market (TAM)
The global life science and diagnostics market is estimated to be in the hundreds of billions USD. Thermo Fisher Scientific Inc. is well-positioned to capture a significant share of this TAM due to its diversified offerings and strong market presence.
Upturn SWOT Analysis
Strengths
- Diversified product portfolio
- Global presence
- Strong brand reputation
- Extensive distribution network
- Strong financial performance
- Robust innovation pipeline
Weaknesses
- Integration challenges from acquisitions
- Exposure to cyclical R&D spending
- Dependence on key suppliers
- High debt load
Opportunities
- Growing demand for personalized medicine
- Expansion in emerging markets
- Increasing adoption of automation in laboratories
- Strategic acquisitions to expand product offerings
- Growth in bioproduction market
Threats
- Intense competition
- Economic downturns impacting R&D budgets
- Regulatory changes
- Pricing pressure
- Disruptive technologies
Competitors and Market Share
Key Competitors
- DHR
- ABT
- WAT
- AGIL
Competitive Landscape
Thermo Fisher Scientific Inc. has a broad product portfolio and a strong market position, giving it a competitive advantage. However, competition is intense, and the company must continue to innovate and execute its strategy to maintain its lead.
Major Acquisitions
PPD
- Year: 2021
- Acquisition Price (USD millions): 17400
- Strategic Rationale: Expanded clinical research services capabilities, strengthening its position in the pharmaceutical services market.
Brammer Bio
- Year: 2019
- Acquisition Price (USD millions): 1700
- Strategic Rationale: Strengthened gene therapy manufacturing capabilities.
Growth Trajectory and Initiatives
Historical Growth: Thermo Fisher Scientific Inc. has experienced significant growth through organic initiatives and acquisitions.
Future Projections: Analysts project continued revenue and earnings growth, driven by favorable industry trends and the company's strategic initiatives.
Recent Initiatives: Recent initiatives include strategic acquisitions, investments in R&D, and expansion in emerging markets.
Summary
Thermo Fisher Scientific is a strong company with a diversified product portfolio, a global presence, and a solid financial performance. Their growth trajectory is promising, driven by strategic acquisitions and organic expansion. However, they should be aware of the challenges involved with integration of companies, fierce competition and future potential cyclical impacts to R&D budgets. The high debt load will need to be monitored.
Similar Companies
ABT
Abbott Laboratories
ABT
Abbott Laboratories
DHR
Danaher Corporation
DHR
Danaher Corporation
HON
Honeywell International Inc
HON
Honeywell International Inc
MMM
3M Company
MMM
3M Company
WAT
Waters Corporation
WAT
Waters Corporation
Sources and Disclaimers
Data Sources:
- Thermo Fisher Scientific Inc. Investor Relations
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market conditions and company performance can change rapidly, and past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Thermo Fisher Scientific Inc
Exchange NYSE | Headquaters Waltham, MA, United States | ||
IPO Launch date 1978-01-13 | Chairman, President & CEO Mr. Marc N. Casper | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 125000 | Website https://www.thermofisher.com |
Full time employees 125000 | Website https://www.thermofisher.com | ||
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, as well as diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment includes clinical diagnostics offering liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, protein detection assays, and instruments; immunodiagnostics offers develops, manufactures, and markets complete blood test systems to support the clinical diagnosis and monitoring of allergy, asthma, and autoimmune diseases; microbiology offers dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; transplant diagnostics products include human leukocyte antigen typing and testing for organ transplant market; and healthcare market channel offers consumables, diagnostic kits and reagents, equipment, instruments, solutions, and services. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. It offers products and services through a direct sales force, customer-service professionals, electronic commerce, and third-party distributors under Thermo Scientific; Applied Biosystems; Invitrogen; Fisher Scientific; Unity Lab Services; and Patheon and PPD. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.